NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

NCT07556549

Active Not RecruitingN/A

Sponsor: Pfizer

Conditions: Non-Small Cell Lung Cancer ALK-positive

Interventions: Lorlatinib

Countries: China

The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC. The participants included in this study are: * Aged 18 years or more * diagnosed with a/mNSCLC * confirmed with testing for ALK-positive * have started first-line lorlatinib treatment during the patient selection period In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Age ≥18 years
2. Diagnosed with a/mNSCLC
3. Confirmed testing for ALK-positive
4. Initiated first-line lorlatinib treatment during the patient selection period, prior therapy such as adjuvant or neoadjuvant treatment are allowed.
5. A minimum lookback period of at least 3 months to establish a baseline period and ensure first-line use of cohort entry drug
6. Have at least 6 months of follow-up data available (early death or progression will be included)

Locations (1)

Beijing, China